Insulin Glargine Biosimilar (Abasaglar®)
Indication
Type 1 and Type 2 diabetes mellitus
Green
Brand:
Abasaglar®
Nice TA:
Commissioning responsibility:
CCG
PbR excluded:
No
BNF chapter:
Endocrine system
Background
Must be commenced by a healthcare professional who is appropriately trained and experienced in the initiation of insulin.
Biosimilars of insulin glargine 100 units/mL (Lantus®) are recommended for use in patients with type 1 and type 2 diabetes mellitus. The prescribing of biosimilar preparations should be by brand name, followed by the concentration and recommended daily dose in units and a statement of the formulation. Treatment should normally be started with the least expensive drug.
The initiation of biosimilar insulins should be in NEW patients or patients assessed to need a medication change, with close monitoring of their blood glucose to ensure good control is achieved.
The LSCMMG recommends Abasaglar KwikPen® as the 1st line long-acting insulin analogue.
Recommendation
LSCMMG Recommendation:
Green
Reason for decision:
Suitable for initiation in primary care
Supporting documents: